Benzinga | Jan 12, 2022 08:59AM EST

Wedbush Maintains Neutral on Biogen, Lowers Price Target to $195

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $249 to $195.